<?xml version="1.0" encoding="UTF-8"?>
<ref id="B30-vaccines-07-00046">
 <label>30.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhao</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>He</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Qiu</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Tai</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Y.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV</article-title>
  <source>J. Virol.</source>
  <year>2018</year>
  <pub-id pub-id-type="doi">10.1128/JVI.00837-18</pub-id>
 </element-citation>
</ref>
